Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Lanas, J.M. Piqué, J. Ponce.
Estrategia clínica para el paciente que precisa antiinflamatorios no esteroides: posición de los inhibidores de la COX-2.
Gastroenterol Hepatol, 24 (2001), pp. 22-36
[2.]
S.E. Gabriel, L. Jaakkimainen, C. Bombardier.
Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis.
Ann Intern Med, 115 (1991), pp. 787-796
[3.]
F.E. Silverstein, D.Y. Graham, J.R. Senior, H.W. Davies, B.J. Struthers, R.M. Bittman, et al.
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med, 123 (1995), pp. 241-249
[4.]
S. Hernández-Díaz, L.A. García Rodríguez.
Epidemiologic assessment of the safety of conventional nonsteroidal antiinflmmatory drugs.
Am J Med, 110 (2001), pp. S20-S27
[5.]
L. Laine, C. Bombardier, C. Hawkey, B. Davis, D. Shapiro, C. Brett, et al.
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.
Gastroenterology, 123 (2002), pp. 1006-1012
[6.]
J. Messer, D. Reitman, H.S. Sacks, H. Smith, T.C. Chalmers.
Association of adrenocorticosteroid therapy and peptic-ulcer disease.
N Engl J Med, 309 (1983), pp. 619-632
[7.]
H. Conn, T. Poynard.
Corticosteroids and peptic ulcer: metaanalysis of adverse events during steroid therapy.
J Intern Med, 236 (1994), pp. 619-632
[8.]
S. Hernández-Díaz, L.A. García Rodríguez.
Steroids and risk of upper gastrointestinal complications.
Am J Epidemiol, 153 (2001), pp. 1089-1093
[9.]
L.A. García Rodríguez, S. Hernández-Díaz.
The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetamonophen, and combinations of these agents.
Arthritis Res, 3 (2001), pp. 98-101
[10.]
S.P. Johnsen, H.T. Sorensen, L. Mellemkjoer, W.J. Blot, G.L. Nielsen, J.K. McLaughlin, et al.
Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants.
Thromb Haemost, 86 (2001), pp. 563-568
[11.]
J. Weil, M.J. Langman, P. Wainwright, D.H. Lawson, M. Rawlins, R.F. Logan.
et al Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs.
Gut, 46 (2000), pp. 27-31
[12.]
R.I. Schorr, W.A. Ray, J.R. Daugherty, M.R. Griffin.
Concurrent use of nosteroidal antiinnflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorragic peptic ulcer disease.
Arch Intern Med, 153 (1993), pp. 1665-1670
[13.]
EAJ. Knifff-Dutmer.
Concomitant coumarin-NSAID therapy and risk for bleeding.
Ann Pharmacoth, 37 (2003), pp. 12-16
[14.]
A. Pardo, M. Garcia-Losa, A. Fernandez-Pavon, S. Del Castillo, T. Pascual-García, et al.
A placebo controlled stady of interaction between nabumetone and acenocoumarol.
Br J Clin Pharmacol, 47 (1999), pp. 441-444
[15.]
L. Laine, S. Harper, T. Simon, R. Bath, J. Johanson, H. Schwartz, et al.
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.
Gastroenterology, 117 (1999), pp. 776-783
[16.]
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, et al.
Comparison of upper gastrointestinal toxi-city of rofecoxib and naproxen in patients with rheumatoid arthritis.
N Engl J Med, 343 (2000), pp. 1520-1528
[17.]
T.Y. Chan.
Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance.
Ann Pharmacother, 29 (1995), pp. 1274-1283
[18.]
A. Van Hecken, J.I. Schwartz, M. Depré, I. Lepeleire, A. Dallob, L. Tanaka, et al.
Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, naproxen on COX-2 versus COX-1 in healthy volunteers.
J Clin Pharmacol, 40 (2000), pp. 1109-1120
[19.]
A. Karim, D. Tolbert, A. Piergies, R.C. Hubbard, K. Harper, C.B. Wallemark, et al.
Celecoxib does not significantly alter the pharmacokinetics or hypoprotrombinemic effect of warfarin in healthy subjects.
J Clin Pharmacol, 40 (2000), pp. 655-663
[20.]
E.A. Knijff-Dutmer, A. Martens, M.A. Van der Laar.
Effects of Nabumetone compared with Naprosen on platelet agregation in patients with rheumatoid arthritis.
Ann Rheum Dis, 58 (1999), pp. 257-259
[21.]
A. Buvanendran, D. Elmofty, K.J. Tuman, M. Scheinkop, J.S. Kroin.
Administration of selective cyclooxygenase-2 inhibitor with warfarin does not increase blood loss following total knee arthroplasty (TKA).
Anesthesiology, 96 (2002), pp. A-942
[22.]
D.Y. Graham, J.L. Smith, S.M. Dobbs.
Gastric adaptation occurs with aspirin administration in man.
Am J Dig Dis, 28 (1983), pp. 1-6
[23.]
M.V. Skeljo, G.A. Cook, S.L. Elliot, A.S. Giraud, N.D. Yeomans.
Gastric mucosal adaptation to diclofenac injury.
Dig Dis Sci, 41 (1996), pp. 32-39
[24.]
J. Stachura, J.W. Konturek, A. Dembinski, W. Domschke.
Growth markers in the human gastric mucosa during adaptation to continued aspirin administration.
J Clin Gastroenterol, 22 (1996), pp. 282-287
[25.]
S. Hernández-Díaz, L.A. García Rodríguez.
Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/ perforation.
Arch Intern Med, 160 (2000), pp. 2093-2099
[26.]
J.W. Konturek, A. Dembinski, S.J. Konturek, J. Stachura, W. Domschke.
Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans.
Gastroenterology, 114 (1998), pp. 245-255
[27.]
G.R. Lipscomb, F. Campbell, W.D. Rees.
The influence of age gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non-steroidal antinflammatory drugs.
Aliment Pharmacol Ther, 11 (1997), pp. 907-912
[28.]
S.P. Gutthann, L.A. Garcia Rodriguez, D.S. Raiford.
Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation.
Epidemiology, 8 (1997), pp. 18-24
[29.]
D. Henry, A. Dobson, C. Turner.
Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs.
Gastroenterology, 105 (1993), pp. 1078-1088
[30.]
M.R. Griffin, J.M. Piper, J.R. Daugherty, M. Snowden, W.A. Ray.
Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons.
Ann Intern Med, 114 (1991), pp. 257-263
[31.]
L.A. García Rodríguez, H. Jick.
Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.
Lancet, 343 (1994), pp. 769-772
[32.]
L.A. García Rodríguez, C.H. Cattaruzzi, M.G. Troncon, L. Agostinis.
Risk of hospitalization for upper gastrointestinal bleeding associated with ketorolack, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs.
Arch Intern Med, 158 (1998), pp. 33-39
[33.]
J.R. Laporte, X. Carné, X. Vidal, V. Moreno, J. Juan.
Upper gastrointestinal bleeding in relation to previous use of analgesic and non-steroidal anti-inflammatory drugs.
Lancet, 1 (1991), pp. 85-89
[34.]
W.E. Smalley, W.A. Ray, J.R. Daugherty, M.R. Griffin.
Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons.
Am J Epidemiol, 141 (1995), pp. 539-545
[35.]
J. Hallas, J. Lauritsen, H.D. Villadsen, L.F. Gram.
Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding identifying high-risk groups by excess risk estimates.
Scand J Gastroenterol, 30 (1995), pp. 438-444
[36.]
M.J. Langman, J. Weil, P. Wainwright, D.H. Lawson, M.D. Rawlins, R.F. Logan, et al.
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.
Lancet, 343 (1994), pp. 1075-1078
[37.]
J.M. Hansen, J. Hallas, J.M. Lauritsen, P. Bytzer.
Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making.
Scand J Gastroenterol, 31 (1996), pp. 126-130
[38.]
L.S. Simon, H.T. Hatoum, R.M. Bittman, W.T. Archambault, R.P. Polisson.
Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
Fam Med, 28 (1996), pp. 204-210
[39.]
A. Lanas, E. Bajador, P. Serrano, J. Fuentes, S. Carreño, J. Guardia, et al.
Nitrovasodilators, low-dose aspirin, nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding.
N Engl J Med, 343 (2000), pp. 834-839
[40.]
J.M. Piper, W.A. Ray, J.R. Daugherty, M.R. Griffin.
Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs.
Ann Intern Med, 114 (1991), pp. 735-740
[41.]
M. Imhof, C. Ohmann, A. Hartwig, K.P. Thon, K.J. Hengels, H.D. Roher.
Which peptic ulcers bleed?.
Results of a case-control study. DUSUK Study Group. Scand J Gastroenterol, 32 (1997), pp. 131-138
[42.]
A. Lanas, P. Serrano, E. Bajador, F. Esteva, R. Benito, R. Sainz.
Evidence of aspirin use in both upper and lower gastrointestinal perforation.
Gastroenterology, 112 (1997), pp. 683-689
[43.]
N.D. Yeomans, Z. Tulassay, L. Juhász, I. Rácz, J.M. Howard, C.J. Van Rensburg, et al.
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group.
N Engl J Med, 338 (1998), pp. 719-726
[44.]
C.J. Hawkey, J.A. Karrasch, L. Szczepanski, D.G. Walker, A. Barkun, A.J. Swannell, et al.
Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group.
N Engl J Med, 338 (1998), pp. 727-734
[45.]
D.Y. Graham, N.M. Agrawal, D.R. Campbell, M.M. Haber, C. Collis, N.L. Lukasik, et al.
Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs. Results of a doubleblind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs lansoprazole.
Arch Intern Med, 162 (2002), pp. 169-175
[46.]
F.K. Chan, S.C. Chung, B.Y. Suen, Y.T. Lee, W.K. Leung, V.K. Leung, et al.
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.
N Engl J Med, 344 (2001), pp. 967-973
[47.]
F.K. Chan, L.C. Hung, B.Y. Suen, J.C. Wu, K.C. Lee, V.K. Leung, et al.
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
N Engl J Med, 347 (2002), pp. 2104-2110
[48.]
L.S. Simon, H.T. Hatoum, R.M. Bittman, W.T. Archambault, R.P. Polisson.
Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
Fam Med, 28 (1996), pp. 204-210
[49.]
S. Santolaria, A. Lanas, R. Benito, M.A. Pérez-Aisa, M. Montoro, R. Sainz.
Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users.
Aliment Pharmacol Ther, 13 (1999), pp. 1511-1518
[50.]
C. Aalykke, J.M. Lauritsen, J. Hallas, S. Reinholdt, K. Krogfelt, K. Lauritsen.
Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a casecontrol study.
Gastroenterology, 116 (1999), pp. 1305-1309
[51.]
D.J. Cullen, G.M. Hawkey, D.C. Greenwood, H. Humphreys, V. Shepherd, R.F. Logan.
et al Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs.
Gut, 41 (1997), pp. 459-462
[52.]
C.Y. Wu, S.K. Poon, G.H. Chen, C.S. Chang, H.Z. Yeh.
Interaction between Helicobacter pylori and nonsteroidal antiinflammatory drugs in peptic ulcer bleeding.
Scand J Gastroenterol, 33 (1998), pp. 234-237
[53.]
A. Pilotto, G. Leandro, F. Di Mario, M. Franceschi, L. Bozzola, G. Valerio.
Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly. A case-control study.
Dig Dis Sci, 42 (1997), pp. 586-591
[54.]
J. Labenz, U. Peitz, H. Köhl, J. Kaiser, P. Malfertheiner, A. Hackelsberger, et al.
Helicobacter pylori increases the risk of peptic ulcer bleeding: a case-control study.
Ital J Gastroenterol Hepatol, 31 (1999), pp. 110-115
[55.]
T.M. Ng, K.M. Fock, J.L. Khor, E.K. Teo, C.S. Sim, A.L. Tan, et al.
Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer.
Aliment Pharmacol Ther, 14 (2000), pp. 203-209
[56.]
C.J. Hawkey.
Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs.
Gut, 46 (2000), pp. 310-311
[57.]
E.K. Li, J.J. Sung, R. Suen, T.K. Ling, V.K. Leung, E. Hui, et al.
Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs.
Scand J Rheumatol, 25 (1996), pp. 42-46
[58.]
A. Pilotto, M. Franceschi, G. Leandro, F. Di Mario, G. Valerio.
The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly.
Eur J Gastroenterol Hepatol, 9 (1997), pp. 951-956
[59.]
A.S. Taha, R.D. Sturrock, R.I. Russell.
Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori.
Gut, 36 (1995), pp. 334-336
[60.]
M. Janssen, B.A. Dijkmans, C.B. Lamers, A.H. Zwinderman, J.P. Vandenbroucke.
A gastroscopic study of the predictive value of risk factors for non-steroidal anti-inflammatory drug associated ulcer disease in rheumatoid arthritis patients.
Br J Rheumatol, 33 (1994), pp. 449-459
[61.]
J.G. Kim, D.Y. Graham.
and The Misoprostol Study Group. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy.
Am J Gastroenterol, 89 (1994), pp. 203-207
[62.]
M. Voutilainen, T. Sokka, M. Juhola, M. Farkkila, P. Hannonen.
Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer.
Scand J Gastroenterol, 33 (1998), pp. 811-816
[63.]
F.K. Chan, J.J. Sung, S.C. Chung, K.F. To, M.Y. Yung, V.K. Leung, et al.
Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.
Lancet, 350 (1997), pp. 975-979
[64.]
G. Bianchi Porro, F. Parente, V. Imbesi, F. Montrone, I. Caruso.
Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long-term NSAID users. Response to omeprazole dual therapy.
Gut, 39 (1996), pp. 22-26
[65.]
C.J. Hawkey, Z. Tulassay, L. Szczepanski, C.J. Van Rensburg, A. Filipowicz-Sosnowska, A. Lanas, et al.
Randomised controlled trial of Helicobacter pylori eradication in patients on nonsteroidal anti-inflammatory drugs:.
HELP NSAIDs study Lancet, 352 (1998), pp. 1016-1021
[66.]
J.Q. Huang, S. Sridhar, R.H. Hunt.
Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease: a meta-analysis.
Lancet, 359 (2002), pp. 14-22
[67.]
J. Labenz, A.L. Blum, W.W. Bolten, B. Dragosics, W. Rosch, M. Stolte, et al.
Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.
Gut, 51 (2002), pp. 329-335
[68.]
W.A. Stack, J.C. Atherton, G.M. Hawkey, R.F. Logan, C.J. Hawkey.
Interaction between Helicobacter pylori and other risk factors for peptic ulcer bleeding.
Aliment Pharmacol Ther, 16 (2002), pp. 497-506
[69.]
L. Laine.
Review article: the effect of Helicobacter pylori infection on nonsteroidal anti-inflammatory drug-induced upper gastrointestinal tract injury.
Aliment Pharmacol Ther, 16 (2002), pp. 34-39
[70.]
J.M. Scheiman, R.R. Bandekar, M.E. Chernew, A.M. Fendrick.
Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis.
Aliment Pharmacol Ther, 15 (2001), pp. 63-71
[71.]
C.W. Ko, R.A. Deyo.
Cost-effectiveness of strategies for primary prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcer disease.
J Gen Intern Med, 15 (2000), pp. 400-410
[72.]
C.J. Hawkey, I. Wilson, J. Naesdal, G. Langstrom, A.J. Swannell, N.D. Yeomans.
Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users.
Gut, 51 (2002), pp. 344-350
[73.]
D.R. Campbell, M.M. Haber, E. Sheldon, C. Collis, N. Lukasik, B. Huang, et al.
Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
Am J Gastroenterol, 97 (2002), pp. 2208-2214
[74.]
X. Calvet, J. Gratacos, J. Font, M. Larrosa, I. Sanfeliu, M. Roque.
Helicobacter pylori does not play a part in the dyspeptic complaints of rheumatology patients receiving long term treatment with non-steroidal anti-inflammatory drugs.
Ann Rheum Dis, 61 (2002), pp. 641-643
[75.]
B. Bannwarth, E. Dorval, A. Caekaert, P. Barthelemy.
Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal antiinflammatory drugs combined with omeprazole.
J Rheumatol, 29 (2002), pp. 1975-1980
[76.]
S. Derry, Y.K. Loke.
Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis.
BMJ, 321 (2000), pp. 1183-1187
[77.]
P. Serrano, A. Lanas, M.T. Arroyo, I.J. Ferreira.
Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases.
Aliment Pharmacol Ther, 16 (2002), pp. 1945-1953
[78.]
F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, et al.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial.
JAMA, 284 (2000), pp. 1247-1255
[79.]
J.L. Goldstein, G. Eisen, W. Bensen.
SUCCESS in osteoarthritis (OA) trial: celecoxib significantly reduces the risk of upper gastrointestinal (UGI) hospitalizations compared to diclofenac and naproxen in 13,274 randomized patients with OA [abstract].
pp. 13-16
[80.]
M.J. Langman, D.M. Jensen, D.J. Watson, S.E. Harper, P. Zhao, H.H. Quan, et al.
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
JAMA, 282 (1999), pp. 1929-1933
[81.]
G.P. Geba, A.B. Polis, C.S. Skalky, R.A. Petruschke, T.W. Dobbins.
Rofecoxib versus naproxen in osteoarthritis patients receiving concomitant low dose aspirin: a subgroup analysis involving 719 patients fron the ADVANTAGE trial.
European League Against Rheumatism; Stockholm, June, (2002), pp. 12-15
[82.]
J.J. Deeks, L.A. Smith, M.D. Bradley.
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
BMJ, 325 (2002), pp. 619
[83.]
A. Lanas, M.C. Sekar, B.I. Hirschowitz.
Objetive evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding.
Gastroenterology, 103 (1992), pp. 862-869
[84.]
C.M. Wilcox, L.N. Alexander, G.A. Cotsonis, W.S. Clark.
Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding.
Dig Dis Sci, 42 (1997), pp. 990-997
[85.]
E. Smecuol, J.C. Bai, E. Sugai, H. Vázquez, S. Niveloni, S. Pedreira, et al.
Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs.
Gut, 49 (2001), pp. 650-655
[86.]
G. Sigthorsson, R. Crane, T. Simon, M. Hoover, H. Quan, J. Bolognese, et al.
COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin.
Gut, 47 (2000), pp. 527-532
[87.]
R.H. Hunt, B. Bowen, E.R. Mortensen, T.J. Simon, C. James, A. Cagliola, et al.
A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.
Am J Med, 109 (2000), pp. 201-206
[88.]
A. Lanas, J. Fuentes, R. Benito, P. Serrano, E. Bajador, R. Sainz.
Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin.
Aliment Pharmacol Ther, 16 (2002), pp. 779-786
[89.]
G.H. Rao, G.G. Johnson, K.R. Reddy, J.G. White.
Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin.
Arteriosclerosis, 3 (1983), pp. 383-388
[90.]
F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. De Marco, B. Tournier, et al.
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
N Engl J Med, 345 (2002), pp. 1089-1117
[91.]
A. Lanas, P. Serrano, E. Bajador, J. Fuentes, R. Sáinz.
Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs.
Eur J Gastroenterol Hepatol, 15 (2003), pp. 1-6
[92.]
J. Matias-Guiu, J. Ferro, J. Álvarez-Sabín, F. Torres.
Triflusal versus aspirin in secondary stroke prevention: results of TACIP study [abstract 73].
Stroke, 32 (2001), pp. 329
[93.]
CAPRIE Steering Committee.
A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischemic event (CAPRIE).
Lancet, 348 (1996), pp. 1329-1339
[94.]
R.A. Sheikh, P.S. Romano, T.P. Prindiville, S. Yasmeen, W. Trudeau.
Endoscopic evidence of mucosal injury in patients taking ticlopidine compared with patients taking aspirin/nonsteroidal antiinflammatory drugs and controls.
J Clin Gastroenterol, 34 (2002), pp. 529-532
[95.]
W.K. Hass, J.D. Easton, H.P. Adams Jr, W. Pryse-Phillips, B.A. Molony, S. Anderson, et al.
Randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.
N Engl J Med, 321 (1989), pp. 501-507
[96.]
M. Ruggeri, G. Castaman, F. Rodeghiero.
Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders?.
Haematologica, 78 (1993), pp. 18-21
[97.]
J.B. Forrest, F. Camu, I.A. Greer, H. Kehlet, M. Abdalla, F. Bonnet, et al.
Ketorolac, Diclofenac and Ketoprofen are equally safe for pain relief after major surgery.
Br J Anesthesia, 88 (2002), pp. 227-233
[98.]
Langman MJS.
Risks of antiinflammatory drug-associated damage.
Inflamm Res, 48 (1999), pp. 236-238
[99.]
C. Bombardier.
An evidence-based evaluation of the gastrointestinal safety of coxibs.
Am J Cardiol, 89 (2002), pp. D3-D9
[100.]
M. Ouellet, D. Riendeau, M.D. Percival.
A high level of cyclooxigenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
PNAS, 98 (2001), pp. 14583-14588
[101.]
P.T. Leese, R.C. Hubbard, A. Karim, P.C. Isakson, S.S. Yu, G.S. Geis.
Effects of Celecoxib, a novel cyclooxigenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial.
J Clin Pharmacol, 40 (2000), pp. 124-132
[102.]
M. Depré, E.W. Ehrich, A. Van Hencken, I. Lepeleire, A. Dallob, P. Wong.
Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans.
Eur J Clin Pharmacol, 56 (2000), pp. 167-174
[103.]
S.S. Reuben, N.R. Connelly.
Postoperative analgesic effects of Celecoxib or Rofecoxib after spinal fusion surgery.
Anesth Analg, 91 (2000), pp. 1221-1225
[104.]
J.E. Edwards, F. Meseguer, C.C. Faura, R.A. Moore, H.J. McQuay.
Single-dose dipyrone for acute postoperative pain.
Cochrane Database Syst Rev, 3 (2001), pp. CD003227
[105.]
G. Bianchi Porro, S. Ardizzone, M. Petrillo, I. Caruso, F. Montrone.
Endoscopic assessment of the effects of dipyrone (metamizol) in comparison to paracetamol and placebo on the gastric and duodenal mucosa of healthy adult volunteers.
Digestion, 57 (1996), pp. 186-190
[106.]
S. Sánchez, M.J. Martín, P. Ortíz, V. Motilva, C. Alarcón de la Lastra.
Effects of dipyrone on inflammatory infiltration and oxidative metabolism in gastric mucosa.
Dig Dis Sci, 47 (2002), pp. 1389-1398
[107.]
A. Lanas, P. Serrano, E. Bajador, J. Fuentes, R. Sáinz.
Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs.
Eur J Gastroenterol Hepatol, 15 (2003), pp. 1-6
[108.]
R.J. Flower, J.R. Vane.
Inhibition of prostaglandin synthase in brain explains the anti-pyrectic activity of paracetamol.
Nature, 240 (1972), pp. 410-411
[109.]
F.L. Lanza, J.R. Codispoti, E.B. Nelson.
An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketaprofen and acetominophen.
Am J Gastroenterol, 93 (1998), pp. 1051-1054
[110.]
T.P. Jerussi, J.F. Caubet, J.E. McCray, D.A. Handley.
Clinical endoscopic evaluation of the gastroduodenal tolerance to R-ketoprofen, R-flubirprofen, racemic ketoprofen and paracetamol: a randomized, single-blind, placebo-controlled trial.
J Clin Pharmacol, 38 (1998), pp. S19-S24
[111.]
P. Muller, B. Simon, D. Weise, H.G. Dammann.
Endoscopic studies on the gastric tolerance of paracetamol and acetylsalicylic acid: a placebo-controlled, double-blind study in healthy volunteers.
Arzneimittelforschung, 40 (2000), pp. 316-318
[112.]
A.R. Moore, E. Van Gansen, J.M. Le Parc, R. Wall, H. Scheid, M. Farhan, et al.
The PAIN study: paracetamol, aspirin, ibuprofen new tolerability. A large scale, randomised clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short term analgesia.
Clin Drug Invest, 18 (1999), pp. 89-98
[113.]
J.D. Bradley, K.D. Brandt, B.P. Katz, L.A. Kalasinski, S.I. Ryan.
Comparison of an anti-inflammatory dose of iburpfen, and analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
N Engl J Med, 325 (1991), pp. 87-91
[114.]
G.P. Geba, A.L. Weaver, A.B. Polis, M.E. Dixon, T.J. Schnitzer.
Efficacy of Rofecoxib, Celecoxib, and Acetaminophen in Osteoarthritis of the Knee.
JAMA, 287 (2002), pp. 64-71
[115.]
J.C. Silverfield, M. Kamin, S.C. Wu, N. Rosenthal.
and CAPSS-105 Study Group. Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study.
Clin Ther, 24 (2002), pp. 282-297
[116.]
E. Rahme, D. Pettitt, J. LeLorier.
Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population.
Arthritis & Rheum, 46 (2002), pp. 3046-3054
[117.]
L.A. García Rodríguez, S. Hernández-Díaz.
Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs.
Epidemiology, 12 (2001), pp. 570-576
[118.]
M.U. Werner, P.R. Nielsen, J. Romsing, L.A. García Rodríguez, S. Hernández-Díaz.
Acetaminophen and upper gastrointestinal complications.
Epidemiology, 13 (2002), pp. 605-607
[119.]
T. Pincus, G. Koch, T. Sokka, J. Lefkowith, F. Wolfe, J.M. Jordan, et al.
A randomised, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee.
Arthritis Rheum, 44 (2001), pp. 1587-1598
[120.]
P. Rampal, N. Moore, E. VanGanse, J.M. La Parc, R. Wall, H. Schneid, et al.
Gastrointestinal tolerability of ibuprofen compared with paracetamol and aspirin at over-the-counter doses.
J Int Med Res, 30 (2002), pp. 301-308
[121.]
D.Y. Graham, J.L. Smith.
Effects of aspirin and an aspirin-acetaminophen combination on the gastric mucosa in normal subjects. A double-blind endoscopic study.
Gastroenterology, 88 (1985), pp. 1922-1925
[122.]
A.I. Stern, D.L. Hogan, L.H. Kahn, J.I. Isenberg.
Protective effect of acetaminophen against aspirin-and ethanol-induced damage to the human gastric mucosa.
Gastroenterology, 86 (1984), pp. 728-733
[123.]
J.M. Seager, C.J. Hawkey.
ABC of the upper gastrointestinal tract. Indigestion and non-steroidal anti-inflammatory drugs.
BMJ, 323 (2001), pp. 1236-1239
[124.]
P.G. Hardo, D.M. Chalmers, M. Jakeways, V. Wright.
Axon ATR. Management of NSAIDs-related dyspepsia in the community.
Br J Clin Pract, 47 (1993), pp. 241-242
[125.]
J.H. Van Groenendael, H.M. Markusse, B.A. Dijkmans, F.C. Breedveld.
The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis.
Clin Reumatol, 15 (1996), pp. 450-456
[126.]
A.S. Taha, N. Hudson, C.J. Hawkey, A.J. Swannell, P.N. Trye, J. Cottrell, et al.
Famotidine for the prevention of gastric and duodenla ulcers caused by nonsteroidal antiinflammatory drugs.
N Engl J Med, 334 (1996), pp. 1435-1439
[127.]
P. Ekström, L. Carling, S. Wetterhus, P.E. Wingren, O. Anker-Hansen.
Prevention of peptic ulcer and dispeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy.
Scand J Gastroenterol, 31 (1996), pp. 753-758
[128.]
N.M. Agrawal, D.R. Campbell, M.A. Safdi, N.L. Likasik, B. Huang, M.M. Hhaber.
and NSAIDs-Associated Gastric Ulcer Study Group. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study.
Arch Intern Med, 160 (2000), pp. 1455-1461
[129.]
A. Rostom, G. Wells, P. Tugwell, V. Welch, C. Dube, J. McGowan.
Prevention of NSAID-induced gastroduodenal ulcers (Cochrane Review). The Cochrane Library, Issue 3.
[130.]
J.B. Raskin, R.H. White, R. Jaszewski, M.A. Korsten, T.T. Schubert, J.G. Fort.
Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double.blind, multicenter study.
Am J Gastroenterol, 91 (1996), pp. 223-227
[131.]
M.M. Wolfe, D.R. Lichtenstein, G. Singh.
Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.
N Engl J Med, 340 (1999), pp. 1888-1899
[132.]
G. Singh, D.R. Ramey, D. Morfeld, H. Shi, H.T. Hatoum, J.F. Fries.
Gastrointestinal tract complications of nonsteroidal antiinflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study.
Arch Inter Med, 156 (1996), pp. 1530-1536
[133.]
W.L. Straus, J.J. Ofman, C. MacLean, S. Morton, M.L. Berger, E.A. Roth, et al.
Do NSAIDs cause dyspepsia?. A meta-analysis evaluating alternative dyspepsia definitions.
Am J Gastroenterol, 97 (2002), pp. 1951-1958
[134.]
D.J. Watson, S.E. Harper, P.L. Zhao, H. Quan, J.A. Bolognese, T.J. Simon.
Gastrointestinal tolerability of the selective cyclooxigenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitor in osteoarthritis.
Arch Intern Med, 160 (2000), pp. 2998-3003
[135.]
L. Rabeneck, K. Wristers, J.L. Goldstein, G. Eisen, S.D. Dedhiya, T.A. Burke.
Reliability, validity, and responsiveness of severity of dyspesia assessment (SODA) in a randomized clinical trial of a COX-2-especific inhibitor and traditional NSAID therapy.
Am J Gastroenterol, 97 (2002), pp. 32-39
[136.]
W.G. Bensen, S.Z. Zhao, T.A. Burke, R.A. Zabinski, R.W. Makuch, C.J. Maurath, et al.
Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
J Reumathol, 27 (2000), pp. 1876-1883
[137.]
G.P. Geba, A.B. Polis, C.S. Skalky, R.A. Petruschke, T.W. Dobbins.
Rofecoxib versus naproxen in osteoarthritis patients receiving concomitant low dose aspirin: A subgroup analysis involving 719 patients fron the ADVANTAGE trial.
European League Against Rheumatism; Stockholm, June, (2002), pp. 12-15
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
